Consensus guidelines for diagnosis, prophylaxis and management of Pneumocystis jirovecii pneumonia in patients with haematological and solid malignancies, 2014

Louise A Cooley, Claire Dendle, J Wolf, B W Teh, S C Chen, Craig S Boutlis, Karin A Thursky

Research output: Contribution to journalArticleResearchpeer-review

171 Citations (Scopus)


Pneumocystis jirovecii infection (PJP) is a common cause of pneumonia in patients with cancer-related immunosuppression. There are well-defined patients who are at risk of PJP due to the status of their underlying malignancy, treatment-related immunosuppression and/or concomitant use of corticosteroids. Prophylaxis is highly effective and should be given to all patients at moderate to high risk of PJP. Trimethoprim-sulfamethoxazole is the drug of choice for prophylaxis and treatment, although several alternative agents are available.
Original languageEnglish
Pages (from-to)1350 - 1363
Number of pages14
JournalInternal Medicine Journal
Issue number12b
Publication statusPublished - 2014

Cite this